(63 days)
It is the expressed, intended use of the Oxyheal 1000 Monoplace Hyperbaric Chamber series to provide therapy to those patients with selected medical conditions that have been determined to respond to the application of hyperbaric oxygen. As a Class II prescriptive device, it is further intended for physician involvement in the procurement and routine use.
The conditions listed as appropriate for the use of HBO in the current edition of the Hyperbaric Oxygen Therapy Committee report (2003) are as follows:
- Air or gas embolism
- Carbon monoxide poisoning and carbon monoxide poisoning complicated by cyanide poisoning
- Clostridial myositis and myonecrosis
- Crush injury, compartment syndrome, and other acute traumatic ischemias
- Decompression sickness.
- Enhanced of healing in selected problem wounds
- Exceptional blood loss (anemia)
- Intracranial abscess
- Necrotizing soft tissue infections
- Osteomyelitis (refractory)
- Delayed radiation injury (soft tissue and bony necrosis)
- Skin Grafts and flaps (compromised)
- Thermal burns
The OxyHeal 1000 series is a Class B monoplace hyperbaric chamber system designed to treat 1 patient to a maximum operating pressure of 3 Atmospheres Absolute (ATA) or 30 pounds per square inch gauge (psig). The chamber uses compressed 100% oxygen as the pressurization gas as well as the hyperbaric treatment gas. The overall external length of the chamber is 105" inches. Its internal diameter is 33.5" inches. Pressurization and ventilation is continuously provided by compressed 100% oxygen. The patient breathes the chamber atmosphere directly. An air-break assembly using a regulated medical air source and mask is available. A low-voltage patient intercommunication system provides communications between the patient in the chamber and the outside chamber operator. Single operator chamber pressure control is achieved via a simple industrial adjustable controller with output and input feedback. A pneumatic, manually operated control system is provided for double control redundancy. A series of penetrators are provided in the vessel end caps wall to allow user supplied intravenous lines, suction, medical monitoring leads, etc., to be used as required.
This is a 510(k) premarket notification for a medical device, the OxyHeal 1000 Monoplace Hyperbaric Chamber. This type of submission focuses on demonstrating substantial equivalence to a legally marketed predicate device, rather than proving the device meets specific performance criteria through a study.
Therefore, the provided document does not contain the information requested regarding acceptance criteria and a study proving the device meets them. It describes the device's intended use, its design, and its substantial equivalence to existing predicate devices based on principles of operation and intended use.
Here's a breakdown of why each requested point cannot be addressed from the given text:
-
A table of acceptance criteria and the reported device performance: This document doesn't define specific performance acceptance criteria (e.g., a certain pressure accuracy, oxygen concentration range, or safety feature reliability threshold) nor does it report the results of a study against such criteria. The "performance" described relates to the design and features (e.g., maximum operating pressure, internal diameter, communication system).
-
Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective): No test set, clinical data, or studies are referenced in this document for the OxyHeal 1000 chamber itself. The mention of "extensive data collection" refers to the UHMS's process for validating indications for hyperbaric oxygen therapy, not a study performed on this specific device.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): As no test set or ground truth establishment relevant to this device's performance is described, this information is not present. The UHMS is cited as the authority for indications, but this is a medical society, not a panel establishing ground truth for a device's performance.
-
Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable, as no test set or adjudication process for device performance is mentioned.
-
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This device is a hyperbaric chamber, not an AI-assisted diagnostic or therapeutic tool.
-
If a standalone (i.e. algorithm only without human-in-the loop performance) was done: Not applicable. This device is a physical medical device, not an algorithm.
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not applicable for device performance. The "ground truth" mentioned in the context of hyperbaric oxygen indications comes from scientific validation and verification through extensive data collection by the UHMS.
-
The sample size for the training set: Not applicable, as this is not a machine learning device and no training set is mentioned.
-
How the ground truth for the training set was established: Not applicable, as no training set is described.
In summary, the provided document is a 510(k) summary for a hyperbaric chamber, which focuses on demonstrating substantial equivalence to predicate devices rather than providing detailed performance study results against specific acceptance criteria.
{0}------------------------------------------------
DEC 1 3 2005
Image /page/0/Picture/2 description: The image contains a logo and some text. The logo is a circle with a stylized image of a person sitting in a chair with an asterisk above their head and the number 2 below the chair. To the right of the logo is the text "Hyper Technology Inc.". The logo and text are positioned next to each other.
Technologies
A
Abbreviated 510(k) NOTIFICATION SUMMARY (Per 21 CFR 807.92)
Prepared: 3 March 2005
Trade Name: OxyHeal 1000 Monoplace Hyperbaric chamber
Common Name of Device: Monoplace Hyperbaric Chamber
Classification: 73 CBF, 21 CFR 868.5470
Establishment Registration Number: 2029408
Claimed Predicate Device(s)
Environmental Tectonics Corp. 'Bara-Med" (K020974) Hyperbaric Technologies, Inc. 'OxyHeal 2000' (K011866)
ADDRESS OF MANUFACTURER:
OxyHeal Health Group P.O. Box 1987 La Jolla, CA 92038
・・・・
CONTACT PERSON: DAVE HEANEY Director, Quality Assurance OxyHeal Health Group 3224 Hoover Avenue National City, CA 91950 (619) 336-2022
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the logo for Hyperbaric Technologies Inc. The logo consists of a circular icon on the left and the company name on the right. The icon depicts a person sitting in a chair surrounded by a circular arrow, with the symbol "O2" at the bottom and an asterisk above the person.
EXECUTIVE SUMMARY
The Undersea and Hyperbarics Medical Society (UHMS) defines Hyperbaric oxygen therapy as breathing 100% oxygen at pressures higher that atmospheric in a hyperbaric chamber. According to the National Fire Protection Association (NFPA), hyperbaric chambers are classified into two categories: Class A (multi-occupant) and Class B (single occupant). The OxyHeal 1000 series is a Class B monoplace hyperbaric chamber system designed to treat 1 patient to a maximum operating pressure of 3 Atmospheres Absolute (ATA) or 30 pounds per square inch gauge (psig). The chamber uses compressed 100% oxygen as the pressurization gas as well as the hyperbaric treatment gas.
The OxyHeal 1000 monoplace hyperbaric chamber series are intended to be procured and used by physicians to treat a variety of medical conditions that respond to hyperbaric oxygen. The Undersea and Hyperbaric Medical Society (UHMS) produces a list of medical conditions that have been identified for the appropriate primary or adjunctive use of hyperbaric oxygen. These approved conditions include: air or gas embolism; carbon monoxide poisoning and carbon monoxide poisoning complicated by cyanide poisoning; clostridial myositis and myonecrosis (gas gangrene) ; crush injury, compartment syndrome and other acute traumatic ischemias; decompression sickness; enhancement of healing in selected problem wounds; exceptional blood loss anemia; Intracranial abscess; necrotizing soft tissue infections; osteomyelitis (refractory); delayed radiation injury (soft tissue and bony necrosis); skin flaps and grafts (compromised); and, thermal burns. Aggressive research into the beneficial effects of hyperbaric oxygen, when appropriately applied, will result in additional medical conditions being added to the host of indications by the UHMS.
The Oxyheal 1000 monoplace hyperbaric chamber series is designed and fabricated in accordance with the requirements of the ANSI/ASME Boiler and Pressure Vessel Code, Section VIII, Division 1, Pressure Vessels, ANSI/ASME-PVHO-1 (American Society of Mechanical Engineers-Pressure Vessels for Human Occupancy); and NFPA 99, Health Care Facilities, Chapter 20, Hyperbaric Facilities. The overall external length of the chamber is 105" inches. Its internal diameter is 33.5" inches. These features allow for the state of the art treatment of one (1) patient in comfort. The large cylindrical window create an open atmosphere thus reduce patient confinement anxiety. Pressurization and ventilation is continuously provided by compressed 100% oxygen. The patient breathes the chamber atmosphere directly. An air-break assembly using a regulated medical air source and mask is available.
{2}------------------------------------------------
A low-voltage patient intercommunication system designed and installed in accordance with NFPA 99, Chapter 20 provides communications between the patient in the chamber and the outside chamber operator. It also provides the patient with audio program content from external sources such as TV's, cassette players, radios, etc. A television screen is mounted externally to provide yet another dimension of entertainment.
Single operator chamber pressure control is achieved via a simple industrial adjustable controller with output and input feedback. A pneumatic, manually operated control system is provided for double control redundancy. The rate and direction of pressure change, time at a particular pressure, ventilation rate, fire suppression system, mechanical ventilator and air break assembly are controlled from a single point by the chamber operator, either indirectly with an automatic electronic system or directly by a pneumatic system. A series of penetrators are provided in the vessel end caps wall to allow user supplied intravenous lines, suction, medical monitoring leads, etc., to be used as required.
OxyHeal has concluded that the OxyHeal 1000 Monoplace Hyperbaric Chamber series and its predicate devices have very similar principles of operation. Specifically, the general design approach, method of pressure control and intended use of the OxyHeal 1000 monoplace hyperbaric chamber series are substantially equivalent to the Environmental Tectonics Corp. 'ETC Bara-Med' Monoplace Hyperbaric Chamber (K020974), and the Hyperbaric Technologies, Inc. 'OxyHeal 2000' (K011866) and is proposing them as predicate devices for the Oxyheal 1000 Monoplace Hyperbaric Chamber series.
Intended Use:
It is the expressed, intended use of the Oxyheal 1000 Monoplace Hyperbaric Chamber series to provide therapy to those patients with selected medical conditions that have been determined to respond to the application of hyperbaric oxygen. As a Class II prescriptive device, it is further intended for physician involvement in the procurement and routine use.
The UHMS is the professional medical organization chartered with setting the standards of care defining the appropriate use of hyperbaric oxygen, More specifically , the UHMS publishes a listing of medical conditions that have been clearly established as appropriate primary or adjunctive use of Hyperbaric oxygen (HBO). The disorders on the list have been scientifically validated and verified through extensive data collection. It should be noted
{3}------------------------------------------------
that the list is dynamic. Based on the strength of the scientific data, disorders are both added and removed from the list, depending on the outcomes of scientific pursuit.
The conditions listed as appropriate for the use of HBO in the current edition of the Hyperbaric Oxygen Therapy Committee report (2003) are as follows:
-
- Air or gas embolism
-
- Carbon monoxide poisoning and carbon monoxide poisoning complicated by cyanide poisoning
-
- Clostridial myositis and myonecrosis
-
- Crush injury, compartment syndrome, and other acute traumatic ischemias
-
- Decompression sickness.
-
- Enhanced of healing in selected problem wounds
-
- Exceptional blood loss (anemia)
-
- Intracranial abscess
-
- Necrotizing soft tissue infections
-
- Osteomyelitis (refractory)
-
- Delayed radiation injury (soft tissue and bony necrosis)
-
- Skin Grafts and flaps (compromised)
-
- Thermal burns
The Oxyheal 1000 Monoplace Hyperbaric chamber series is designed to be installed and operated in medical facilities as defined by the NFPA 99, Health Care Facilities, Chapter 20, Hyperbaric Facilities. Further, this system is intended to be operated only by medical personnel specifically trained in the appropriate use of HBO and the safe operations of all related equipment such as the hyperbaric chamber.
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles three overlapping human profiles or abstract shapes.
Public Health Service
DEC 1 3 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. David M. Heaney Director, Quality Assurance OxyHeal Health Group 3224 Hoover Avenue National City, California 91950
Re: K052866
Trade/Device Name: OxyHeal 1000 Monoplace Hyperbaric Chamber Regulation Number: 868.5470 Regulation Name: Hyperbaric Chamber Regulatory Class: II Product Code: CBF Dated: October 5, 2005 Received: October 14, 2005
Dear Mr. Heaney:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{5}------------------------------------------------
Page 2 - Mr. Heaney
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801). please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Snyate y. Michau Omis.
Chíu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
{6}------------------------------------------------
Indications for Use
510(k) Number (if known):
Device Name:
Indications For Use:
-
- Air or Gas Embolism
-
- Carbon Monoxide Poisoning Carbon Monoxide Poisoning Complicated by Cyanide Poisoning
-
- Clostridal Myositis and Myonecrosis (Gas Gangrene)
-
- Crush Injury, Compartment Syndrome, and other Acute Traumatic Ischemias
-
- Decompression Sickness
-
- Enhancement of Healing in Selected Problem Wounds
-
- Exceptional Blood Loss (Anemia)
-
- Intracranial Abscess
-
- Necrotizing Soft Tissue Infections
-
- Osteomyelitis (Refractory)
-
- Delayed Radiation Injury (Soft Tissue and Bony Necrosis)
-
- Skin Grafts & Flaps (Compromised)
-
- Thermal Burns
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Cinn Sylvan
Page 1 of
§ 868.5470 Hyperbaric chamber.
(a)
Identification. A hyperbaric chamber is a device that is intended to increase the environmental oxygen pressure to promote the movement of oxygen from the environment to a patient's tissue by means of pressurization that is greater than atmospheric pressure. This device does not include topical oxygen chambers for extremities (§ 878.5650).(b)
Classification. Class II (performance standards).